METHOD FOR DETERMINING INDIVIDUAL SENSITIVITY TO IMMUNOMODIFIERS IN PATIENTS WITH NEUROALLERGIC SYNDROME OF NEUROINFECTIVE ETIOLOGY

摘要

the invention u043eu0442u043du043eu0441u0438u0442u0441u00a0 to medicine, mainly to u043du0435u0432u0440u043eu043fu0430u0442u043eu043bu043eu0433u0438u0438, and can be used u0434u043bu00a0 u043bu0435u0447u0435u043du0438u00a0 patients u043fu043eu0434u043eu0441u0442u0440u044bu043cu0438 and chronic forms of cer u0435u0431u0440u0430u043bu044cu043du044bu0445 u043du0435u0439u0440u043eu0438u043du0444u0435u043au0446u0438u0439. to improve the accuracy of u0438u0437u043eu0431u0440u0435u0442u0435u043du0438u00a0 u00a0u0432u043bu00a0u0435u0442u0441u00a0 u043eu043fu0440u0435u0434u0435u043bu0435u043du0438u00a0. the purpose of u0434u043eu0441u0442u0438u0433u0430u0435u0442u0441u00a0 so that blood u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 content of circulating u0438u043cu0443u043du043du044bu0445 complexes (cec) and the total level of u043fu0440u043eu0442u0438u0432u043eu043cu043eu0437u0433u043eu0432u044bu0445 antibodies (pma).when the content of cec from 47 to 340 units and the content of pma in response u043fu043eu0442u0440u0435u0431u043bu0435u043du0438u00a0 complement to 15% u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 u0447u0443u0432u0441u0442 - u0432u0438u0442u0435u043bu044cu043du043eu0441u0442u044c to u0438u043cu043cu0443u043du043eu0441u0442u0438u043cu0443u043bu0438u0440u0443u044eu0449u0438u043c drugs, and have cec level 13 46 units. and pma 46% to 90% of u043eu043fu0440u0435u0434u0435u043bu00a0u044eu0442 sensitivity to u0438u043cu043cu0443u043du043eu0434u0435u043fu0440u0435u0441u0441u0438u0440u0443u044eu0449u0438u043c drugs.the invention u043fu043eu0437u0432u043eu043bu00a0u0435u0442 increase time remission in patients with u043du0435u0439u0440u043eu0430u043bu043bu0435u0440u0433u0438u0447u0435u0441u043au0438u043c syndrome u043du0435u0439u0440u043eu0438u043du0444u0435u043au0446u0438u043eu043du043du043eu0433u043e u043fu0440u043eu0438u0441u0445u043eu0436u0434u0435u043du0438u00a0 1.5 years and more in 80.7% of cases by a u0434u0435u043au0432u0430u0442u043du043eu0433u043e choice u0438u043cu043cu0443u043du043eu043au043eu0440u0440u0435u0433u0438u0440u0443u044eu0449u0435u0439 therapy depending on the individual u0438u043cu043cu0443u043du043eu0433u0440u0430u043cu043cu044b and type of immunological reactivity (l